Vultr, the world’s largest privately-held cloud computing platform, proudly announces that Athos Therapeutics, Inc. (“Athos”), a clinical-stage biotechnology company, has chosen Vultr Cloud GPU to power its AI model training, tuning, and inference operations. Leveraging NVIDIA HGX H100 systems and Dell Technologies’ PowerEdge XE9680 servers, Vultr ensures Athos benefits from unparalleled security and confidentiality for their intellectual property, omics data, and proprietary AI algorithms.
Athos is led by a distinguished team including one of the founders of Kite Pharma, the medicinal chemist responsible for two multi-billion-dollar FDA-approved drugs, and the discoverer of the miR-124 drug target, currently in a Phase III IBD trial. The company is at the forefront of AI and ML-based precision small-molecule therapeutics aimed at treating immune-mediated diseases and cancer. By focusing on the molecular complexity of autoimmune and cancer biology, Athos collaborates with leading global hospitals such as the Cleveland Clinic, Lahey Hospital & Medical Center, and the University of Ioannina Medical School to conduct multi-omics analyses on over 25,000 patients. Additionally, Athos partners with Caltech to perform spectrometry-based proteomics using samples from cultured cells and archived, de-identified patient biopsies.
To advance their precision therapeutics, Athos required a flexible, high-performance, and cost-effective cloud infrastructure capable of scaling with their omics data and proprietary AI algorithms while maintaining stringent security and confidentiality. The prohibitive costs and limited engineering support of public cloud providers led Athos to select Vultr. Vultr’s secure and compliant access to NVIDIA GPUs enables Athos to train their AI algorithms efficiently, ensuring all data adheres to local data sovereignty, residency, and privacy regulations.
“Our mission is to democratize access to high-performance cloud compute for the next wave of innovators,” said Amit Rai, General Manager of AI and Enterprise Cloud at Vultr. “For a company like Athos, which operates in a highly regulated industry, security and compliance are paramount. We are honored to provide the scalable, performant, and secure infrastructure that supports Athos in delivering life-changing therapeutics to patients worldwide.”
“Breakthrough medical research demands dynamic and reliable computing power,” added Travis Vigil, Senior Vice President of ISG Product Management at Dell Technologies. “By running on Dell PowerEdge XE9680 servers within Vultr’s cloud platform, we are enabling Athos to securely execute AI workloads at scale and pioneer precision small molecule therapeutics that have the potential to improve countless lives.”
With Vultr’s AI cloud platform, Athos can efficiently train, tune, monitor, and manage a diverse array of AI algorithms while benefiting from:
- Scalable and agile cloud GPU resources: Adapt to growing data needs, simplify GPU management, and reduce long-term AI infrastructure costs.
- User-friendly interface: Facilitate seamless interactions with Vultr’s computational resources, accelerate algorithm training, and eliminate the need for deep technical expertise in GPU configuration.
- Continuous monitoring and management: Optimize resource use, enhance hardware utility, and improve efficiencies.
- Unmatched security, confidentiality, and data sovereignty: Meet global risk and compliance requirements, essential for Athos’ omics data and proprietary AI algorithms.
- 24/7 support: Ensure always-on disaster recovery, engineering support, and maintenance to safeguard Athos’ omics data and AI algorithm checkpoints in case of failures.
“Athos is dedicated to developing novel precision therapeutics for autoimmune diseases and cancer,” said Dimitrios Iliopoulos, PhD, MBA, President & CEO of Athos. “We are thrilled to partner with Vultr and Dell, empowering our AI computational team to achieve this mission using the power of NVIDIA H100 GPUs at scale. Vultr’s support has been instrumental in minimizing downtime and maximizing productivity across our operations.”